Novo Nordisk: Site Expansion Amid Pharma Market Pressures

Novo Nordisk has reported a 10% increase in full-year sales to DKK 309.064bn (US$49.086bn) for 2025. A week after announcing its financial results, the pharmaceutical company revealed plans to expand its Athlone facility in Ireland to manufacture its Wegovy weight loss treatment for markets outside the US.

The expansion comes as the company navigates intensifying competition and anticipates revenue headwinds in 2026.

Chief Financial Officer at Novo Nordisk Karsten Munk Knudsen reflects on the company's performance, stating: "Reporting our full-year results for 2025, we look back on a year where we delivered 10% sales growth, progressed our expanding R&D pipeline, and entered exciting partnerships to bring innovation to millions more patients."

The company's 2025 financial performance was driven primarily by a 41% rise in Wegovy sales, though fourth-quarter results revealed a 2% sales decline and 4% lower operating profit.

Net debt for the full year was reported at DKK 95.424bn (US$15.155bn), following acquisitions made during the period.

Financial outlook signals pricing challenges

Looking ahead to 2026, Novo Nordisk expects sales and operating profit to decline by 5-13%, driven by competition and pricing pressures in the US market, according to Bloomberg.

Karsten addresses the difficult market conditions, noting: "At the same time, we faced intense competition, and, coupled with declining prices, we now expect negative sales growth in 2026, but with continued increase in patient reach and volumes."

CEO Mike Doustdar addresses these challenges in a video on LinkedIn, stating: "Our guidance shows that we will face headwinds from lower drug prices, and we will also be dealing with patent expires, but we will continue to expand and serve more patients this year than ever before."

The company's decision to invest in expanded manufacturing capacity in Ireland indicates confidence in long-term revenue potential despite near-term financial pressures. Mike tells Bloomberg: "If we were about to throw in the towel we would not be investing in factories in Ireland."

Karsten outlines the company's strategic priorities, explaining: "To return to long-term sustainable growth, we remain focused on expanding our position in the growing obesity market, accelerating commercial execution, and investing in our pipeline.

"We are encouraged by the early launch trend for our breakthrough innovation, the first GLP-1 pill for obesity."

New product formats target market expansion

At the start of 2026, Novo Nordisk announced plans to introduce Wegovy in vials in the US to supplement existing pre-filled pens. The vial format, announced on 12 February 2026, could allow for easier and potentially higher-volume manufacturing compared to pen devices.

This followed the introduction of oral Wegovy on 12 January 2026, a once-daily pill available in 1.5mg, 4mg, 9mg and 25mg doses. The oral format is available in the US for a starting cost of US$149 per month.

Ed Cinca, Senior Vice President of Marketing and Patient Solutions at Novo Nordisk, says: "We know there are people who are interested in addressing their weight but have been waiting on the sidelines for a medicine that was right for them.

"For many of them, that wait is over as we can now offer the powerful efficacy of Wegovy in a once-daily pill that demonstrated about 17% weight loss, if all patients stayed on the treatment."

Ireland's position as a major global hub for pharmaceutical manufacturing makes it a strategic location for the expansion. The country consistently ranks as one of the world's top exporters of medicinal and pharmaceutical products.

Market position amid competitive landscape

In a post on LinkedIn on 12 February 2026, Mike writes: "I'm in the US talking to investors and media during a time where Novo Nordisk is getting a lot of headlines and questions. What was my message to them? Two billion people live with obesity, overweight or diabetes worldwide. Our job is simple: serve as many as possible with safe and science-backed options that fit their needs and preferences.

"While it's still early days, I'm encouraged to see that our strategy to expand the market is working: we are in the midst of one of the most successful pharma launches ever.

"This is the direct result of having a strong pipeline, more than 100 years of innovation, manufacturing capabilities that can deliver at global scale and a commercial strategy we've sharpened to focus on what matters most."

The company's commitment to expanding manufacturing in Ireland demonstrates its long-term strategy to maintain market position despite current competitive pressures. The Athlone facility expansion will enable Novo Nordisk to serve international markets more effectively while managing costs and production efficiency.

As the weight loss drug market continues to evolve, Novo Nordisk's multi-pronged approach of expanding manufacturing capacity, introducing new product formats and maintaining investment in research and development positions the company to navigate near-term challenges while pursuing sustainable growth.